Nationwide Ventures co-led a $15m series B round for the health data platform developer that included Aflac Corporate Ventures and Epsilon Health Investors.

LabCorp Venture Fund, Bristol Myers Squibb and Takeda Ventures contributed to $7m in equity funding and a $6m convertible note for the cancer drug developer.

Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.

GV returned for a series C round that helped the precision cancer medicine developer increase its overall funding to over $180m.

Laborie is set to exit the medical device manufacturer after another of its investors, Olympus, announced its intention to pay $260m for its remaining shares.

Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.

The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.

GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.

Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.

Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.